🇺🇸 d-methylphenidate in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Reaction With Eosinophilia And Systemic Symptoms — 2 reports (18.18%)
  2. Off Label Use — 2 reports (18.18%)
  3. Stevens-Johnson Syndrome — 2 reports (18.18%)
  4. Aggression — 1 report (9.09%)
  5. Agitation — 1 report (9.09%)
  6. Conjunctival Hyperaemia — 1 report (9.09%)
  7. Irritability — 1 report (9.09%)
  8. Product Substitution Issue — 1 report (9.09%)

Source database →

d-methylphenidate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is d-methylphenidate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for d-methylphenidate in United States?

University of Cincinnati is the originator. The local marketing authorisation holder may differ — check the official source linked above.